Octagon Research Solutions, INC. Releases STARTINGPOINT 3.2
Octagon Research, a provider of software and services to the life sciences industry, today announced the release of a global document authoring template suite.
Octagon Research Solutions, Inc. Releases startingpoint® 3.2Global Submission Document Authoring Template Suite Includes Over 230 Templates
(WAYNE, PA, November 7, 2008) - CEO & Chairman Jim Walker of Octagon Research Solutions, Inc., a pioneer and leading provider of breakthrough software and services to the life sciences industry, today announced the release of StartingPoint® 3.2. With over 120 clients, Octagon’s StartingPoint global document authoring template suite has proven to be a preferred solution for organizations seeking to standardize their authoring processes in support of electronic submissions.
Some of the new enhancements to StartingPoint 3.2 include:
- Global Configuration File for Document Information Fields - Global settings can be pre-configured minimizing manual entry and ensuring consistent naming conventions across multiple documents.
- Enhanced Physician’s Labeling Rule (PLR) Functionality - Flexibility to format full prescribing information into a one or two column format allowing authors to edit in a single column, but produce two column format for final deliverable.
- New Templates to support ANDA submissions.
- Table and Figure Numbering per Section - Option to number tables and figures either by document or section.
John Lawrie, vice president, Process Solutions at Octagon Research Solutions, Inc. noted, “Evolving global submission standards are adding complexity to the already challenging submission authoring process. Since StartingPoint was first released in 2003, we have worked closely with our internal experts and clients to continue to enhance our suite of templates to support this changing environment. This new release will provide greater flexibility for authors and improve document quality.”
“Octagon’s Process and Regulatory Consultants have been dedicated to the development of this latest version of StartingPoint and their practical expertise is infused into every template,” commented John Rogers, director, Process Solutions. “Our entire portfolio of templates demonstrates the unique combination of domain expertise integrated with enabling technology that is so critical to submission document authoring and that is always associated with Octagon’s solutions.”
To see a demonstration of StartingPoint 3.2 or to learn more about Octagon’s integrated product and service offerings, please contact Octagon Research Solutions, Inc. at (610)-535-6500 or www.octagonresearch.com.
About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading provider of breakthrough software and services to the life sciences industry. Octagon’s eCTD and CDISC solutions provide the people, process and technology required to optimize drug development from data collection to submission. Our regulatory, clinical, process and software offerings provide a unique combination of deep domain knowledge, cross-functional electronic submission expertise, a holistic process approach, and integrated solutions. Octagon is headquartered in Wayne, PA, with European headquarters in Berkhamsted, UK. Octagon’s EDC Operations are located in Mountain View, CA. For more information please visit www.octagonresearch.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
